Literature DB >> 23032616

Gleason score 6 adenocarcinoma: should it be labeled as cancer?

H Ballentine Carter1, Alan W Partin, Patrick C Walsh, Bruce J Trock, Robert W Veltri, William G Nelson, Donald S Coffey, Eric A Singer, Jonathan I Epstein.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 23032616      PMCID： PMC3515766          DOI： 10.1200/JCO.2012.44.0586

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  30 in total

Review 1.  Gleason score 2-4 adenocarcinoma of the prostate on needle biopsy: a diagnosis that should not be made.

Authors:  J I Epstein
Journal:  Am J Surg Pathol       Date:  2000-04       Impact factor: 6.394

2.  Should we really consider Gleason 6 prostate cancer?

Authors:  J Curtis Nickel; Mark Speakman
Journal:  BJU Int       Date:  2011-12-22       Impact factor: 5.588

3.  Call it cancer.

Authors:  Bruce A Chabner; Matthew Smith
Journal:  Oncologist       Date:  2012-02-02

4.  Impact on the clinical outcome of prostate cancer by the 2005 international society of urological pathology modified Gleason grading system.

Authors:  Fei Dong; Chaofu Wang; A Brad Farris; Shulin Wu; Hang Lee; Aria F Olumi; W Scott McDougal; Robert H Young; Chin-Lee Wu
Journal:  Am J Surg Pathol       Date:  2012-06       Impact factor: 6.394

5.  Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols.

Authors:  Viacheslav Iremashvili; Lisét Pelaez; Murugesan Manoharan; Mercé Jorda; Daniel L Rosenberg; Mark S Soloway
Journal:  Eur Urol       Date:  2012-03-17       Impact factor: 20.096

6.  The relationship between clinical benefit and receipt of curative therapy for prostate cancer.

Authors:  Ann C Raldow; Carolyn J Presley; James B Yu; Richa Sharma; Laura D Cramer; Pamela R Soulos; Jessica B Long; Danil V Makarov; Cary P Gross
Journal:  Arch Intern Med       Date:  2012-02-27

7.  Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study.

Authors:  Meelan Bul; Xiaoye Zhu; Antti Rannikko; Frédéric Staerman; Riccardo Valdagni; Tom Pickles; Chris H Bangma; Monique J Roobol
Journal:  Eur Urol       Date:  2012-02-14       Impact factor: 20.096

8.  Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades.

Authors:  Jonathan I Epstein; Zhaoyong Feng; Bruce J Trock; Phillip M Pierorazio
Journal:  Eur Urol       Date:  2012-02-08       Impact factor: 20.096

9.  Growth of high-cost intensity-modulated radiotherapy for prostate cancer raises concerns about overuse.

Authors:  Bruce L Jacobs; Yun Zhang; Ted A Skolarus; Brent K Hollenbeck
Journal:  Health Aff (Millwood)       Date:  2012-04       Impact factor: 6.301

10.  National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer.

Authors:  Patricia A Ganz; John M Barry; Wylie Burke; Nananda F Col; Phaedra S Corso; Everett Dodson; M Elizabeth Hammond; Barry A Kogan; Charles F Lynch; Lee Newcomer; Eric J Seifter; Janet A Tooze; Kasisomayajula Viswanath; Hunter Wessells
Journal:  Ann Intern Med       Date:  2012-02-20       Impact factor: 25.391
View more
  48 in total

1.  [The 2014 consensus conference of the ISUP on Gleason grading of prostatic carcinoma].

Authors:  G Kristiansen; L Egevad; M Amin; B Delahunt; J R Srigley; P A Humphrey; J I Epstein
Journal:  Pathologe       Date:  2016-02       Impact factor: 1.011

2.  Our shifting understanding of factors influencing prostate-specific antigen.

Authors:  Eric A Singer; Robert S DiPaola
Journal:  J Natl Cancer Inst       Date:  2013-08-13       Impact factor: 13.506

3.  Targeted Biopsy to Detect Gleason Score Upgrading during Active Surveillance for Men with Low versus Intermediate Risk Prostate Cancer.

Authors:  Nima Nassiri; Daniel J Margolis; Shyam Natarajan; Devi S Sharma; Jiaoti Huang; Frederick J Dorey; Leonard S Marks
Journal:  J Urol       Date:  2016-09-14       Impact factor: 7.450

4.  Utility of Single-Cell Genomics in Diagnostic Evaluation of Prostate Cancer.

Authors:  Joan Alexander; Jude Kendall; Jean McIndoo; Linda Rodgers; Robert Aboukhalil; Dan Levy; Asya Stepansky; Guoli Sun; Lubomir Chobardjiev; Michael Riggs; Hilary Cox; Inessa Hakker; Dawid G Nowak; Juliana Laze; Elton Llukani; Abhishek Srivastava; Siobhan Gruschow; Shalini S Yadav; Brian Robinson; Gurinder Atwal; Lloyd C Trotman; Herbert Lepor; James Hicks; Michael Wigler; Alexander Krasnitz
Journal:  Cancer Res       Date:  2017-11-27       Impact factor: 12.701

5.  Relationship between Gleason score and apparent diffusion coefficients of diffusion-weighted magnetic resonance imaging in prostate cancer patients.

Authors:  Tae Heon Kim; Chan Kyo Kim; Byung Kwan Park; Hwang Gyun Jeon; Byung Chang Jeong; Seong Il Seo; Hyun Moo Lee; Han Yong Choi; Seong Soo Jeon
Journal:  Can Urol Assoc J       Date:  2016-11-10       Impact factor: 1.862

Review 6.  Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools.

Authors:  Jeffrey J Tosoian; Stacy Loeb; Jonathan I Epstein; Baris Turkbey; Peter L Choyke; Edward M Schaeffer
Journal:  Am Soc Clin Oncol Educ Book       Date:  2016

7.  Use of advanced treatment technologies among men at low risk of dying from prostate cancer.

Authors:  Bruce L Jacobs; Yun Zhang; Florian R Schroeck; Ted A Skolarus; John T Wei; James E Montie; Scott M Gilbert; Seth A Strope; Rodney L Dunn; David C Miller; Brent K Hollenbeck
Journal:  JAMA       Date:  2013-06-26       Impact factor: 56.272

8.  [PREFERE--open questions].

Authors:  C Schäfer; L Weißbach
Journal:  Urologe A       Date:  2014-03       Impact factor: 0.639

9.  Cost-effectiveness of MR Imaging-guided Strategies for Detection of Prostate Cancer in Biopsy-Naive Men.

Authors:  Shivani Pahwa; Nicholas K Schiltz; Lee E Ponsky; Ziang Lu; Mark A Griswold; Vikas Gulani
Journal:  Radiology       Date:  2017-05-17       Impact factor: 11.105

10.  Future-proofing Gleason Grading: What to Call Gleason 6 Prostate Cancer?

Authors:  Stacy Loeb; Francesco Montorsi; James W Catto
Journal:  Eur Urol       Date:  2015-03-11       Impact factor: 20.096
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.